MaaT Pharma announced new appointments to its Board and Executive team. Board of Directors: Karim Dabbagh, PhD, is appointed as Chairman and independent Director, succeeding Jean-Marie Lefèvre who will continue to serve as a Board member. Based in the U.S., Karim Dabbagh, president and CEO of Second Genome Inc., is renowned for his innovative work in microbiome science.

As former executive at Pfizer and Roche, he brings extensive experience in pharmaceutical development. Nadia Kamal, PhD, Director of the Technology, Health, and Innovation Divisions at Harmonie Mutuelle has been appointed as independent director and Chair of the ESG committee. Nadia Kamal has a wealth of experience in Corporate Social Responsibility and a strong background in serving patients and fostering innovation. Appointments to the Executive team and key leaders: Appointment of Professor Gervais Tougas as Acting Chief Medical Officer (CMO): supported by Dr. Emilie Plantamura, Head of Clinical Development, Prof. Tougas will lead medical strategies for MaaT Pharma's registration pathway in onco-hematology and clinical phase in Immuno-oncology.

Prior to joining MaaT Pharma, Gervais was the Head, Chief Medical Officer and Patient Safety at Novartis for almost 20 years. Appointment of Philippe Moyen, as Chief Operating Officer (COO): former Vice-President of technical and business operations for PTC Therapeutics Inc., Philippe Moyen has more than 20 years’ experience in the pharmaceutical and biotech industry, including proven operational excellence and business acumen in small molecules and Biologics that will enable him to effectively contribute to the Company’s future milestones. Guilhaume Debroas, PhD, joins the Company as Head of Investor Relations.

Guilhaume brings instrumental biotech insight and a strong network to enhance communication with the investment community.